Thomas Steen Trawick, Jr.
About Thomas Steen Trawick, Jr.
Independent director of Home Federal Bancorp, Inc. of Louisiana (HFBL) since 2012; age 56. Currently a private-practice physician at Sure Access MD, LLC (since 2024). Previously served as Director, Chief Executive Officer and Chief Medical Officer of CHRISTUS Health Shreveport–Bossier (2019–2023), Associate Chief Medical Officer at Sound Inpatient Physicians, practicing hospitalist at CHRISTUS Health, and earlier private practice at Highland Clinic (2001–2005), followed by pediatric and adult hospitalist work until 2014. Past President of the Northwest Louisiana Medical Society and Speaker of the House of Delegates for the Louisiana State Medical Society .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| CHRISTUS Health Shreveport–Bossier | Director, CEO & CMO | 2019–2023 | Led clinical operations; local medical community leadership |
| Sound Inpatient Physicians | Associate Chief Medical Officer | Not disclosed | Physician leadership |
| CHRISTUS Health | Hospitalist | Not disclosed | Practicing clinician |
| Highland Clinic | Private Practice Physician | Sep 2001–Feb 2005 | Community physician |
| Pediatric & Adult Hospitalist | Hospitalist | Until Jan 2014 | Acute care experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Northwest Louisiana Medical Society | President (past) | Not disclosed | Local medical leadership |
| Louisiana State Medical Society | Speaker, House of Delegates | Not disclosed | State medical governance |
Board Governance
- Independence: Board determined Dr. Trawick is independent under Nasdaq rules .
- Years of service: Director since 2012 .
- Attendance: 73.0% of board and committee meetings in FY2025, below the 75% threshold; board met 10 times .
- Committee assignments and chairs (as of proxy date):
- Audit: Members—Mark M. Harrison; Timothy W. Wilhite; Chair—Scott D. Lawrence .
- Compensation: Members—Mark M. Harrison (Chair); Timothy W. Wilhite; Thomas Steen Trawick, Jr. .
- Nominating & Corporate Governance: Members—Scott D. Lawrence; Chair—Timothy W. Wilhite; Thomas Steen Trawick, Jr. .
- Committee meeting cadence in FY2025: Audit (6), Compensation (6), Nominating (1) .
- Audit Committee financial expert: None designated under SEC rules (members meet Nasdaq financial/accounting background) .
Fixed Compensation
| Element | Amount | Notes |
|---|---|---|
| Board meeting fee | $2,400 per regular meeting (increased to $2,900 starting July 2025) | No fees for special meetings; no separate compensation for Bancorp board attendance |
| Committee meeting fee | $150 per meeting (Audit, Compensation, ALCO, Executive) | Fees unchanged |
| FY2025 director cash fees (Trawick) | $25,050 | From the Director Compensation Table |
Performance Compensation
| Component | Grant/Plan Details | Vesting/COC Terms | FY2025 Value |
|---|---|---|---|
| Stock awards (RSUs/Plan shares) | 2014 Plan (300,000 shares cap, ≤25% share awards); 2019 Plan (250,000 shares cap, ≤25% share awards) | Vest ≤20%/yr; accelerated on death, disability, change-in-control | Trawick: none granted in FY2025; holds 800 outstanding stock awards |
| Stock options | Options to directors under 2014/2019 Plans | Exercisable up to 10 years from grant; post-COC exercisable for remainder of original term; transfer permitted to family/trusts for NQOs; multiple payment methods on exercise | Trawick: option awards reported at $16,250 (FY2025) |
| Performance metrics tied to equity | None disclosed; no awards subject to performance conditions | N/A | N/A |
The Compensation Committee stated it did not time equity grants around MNPI in FY2025 .
Other Directorships & Interlocks
- No other public company directorships disclosed in the proxy for Dr. Trawick .
Expertise & Qualifications
- Physician leader with CEO/CMO experience in regional health system; hospitalist practice background; leadership in local and state medical societies .
- Brings management expertise and knowledge of the local medical community to the board .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Outstanding | Awards/Options exercisable or vesting within 60 days | Pledged/Hedged |
|---|---|---|---|---|
| Thomas Steen Trawick, Jr. | 46,558 | 1.5% | 800 stock awards; 32,000 options | None of directors’/executives’ shares are pledged as security |
| Outstanding equity awards (as of 6/30/2025) | 800 stock awards; 36,000 options (aggregate outstanding) | — | — | — |
Governance Assessment
- Attendance and engagement: 73.0% attendance in FY2025 is a clear RED FLAG versus the 75% minimum disclosure threshold; meeting-based pay structure heightens the signal when attendance underperforms .
- Committee influence: Member of Compensation and Nominating & Corporate Governance, but not a chair—moderate direct governance influence .
- Independence: Affirmed independent under Nasdaq rules—positive for board effectiveness .
- Pay structure and alignment: Director compensation includes both cash and equity (options and plan shares). Equity is time-based rather than performance-based; change-in-control accelerates vesting, which can reduce pay-for-performance rigor—neutral to mildly negative alignment signal for investors focused on performance-conditioned equity .
- Audit oversight context: Audit Committee lacks an SEC-defined “financial expert” (though meets Nasdaq financial/accounting background), a structural oversight weakness; Dr. Trawick is not an Audit member, but overall board risk exists .
- Related-party exposure: Bank extends credit to directors/officers on market terms; Audit Committee reviews and approves related-party transactions per charter—no unfavorable features disclosed (mitigates conflict risk) .
- Ownership alignment: Material personal stake (46,558 shares; 1.5%) with additional options; no pledging—positive alignment signal .
Director Compensation (FY2025)
| Name | Fees Earned or Paid in Cash | Stock Awards | Option Awards | Total |
|---|---|---|---|---|
| Thomas Steen Trawick, Jr. | $25,050 | $0 | $16,250 | $41,300 |
- As of June 30, 2025, outstanding equity awards (directors): Trawick—800 stock awards; 36,000 options .
- As of September 26, 2025 (within 60 days): Trawick—800 stock awards; 32,000 options exercisable .
Committee Assignments (as of proxy date)
| Director | Audit | Compensation | Nominating & Corporate Governance |
|---|---|---|---|
| Mark M. Harrison | Member | Chair | — |
| Scott D. Lawrence | Chair | — | Member |
| Thomas Steen Trawick, Jr. | — | Member | Member |
| Timothy W. Wilhite, Esq. | Member | Member | Chair |
Related Party & Plan Provisions (Equity/COC)
- Vesting and change-in-control: Awards vest ≤20% per year; accelerated upon death, disability, or change-in-control .
- Option term and transferability: Options generally exercisable up to 10 years; NQOs may be transferred to spouse/lineal family/trusts; exercise permitted with cash, broker-assisted, share delivery, or share withholding .
- Related-party transactions: Loans to directors/officers offered on market terms; Audit Committee approval required; no unfavorable features disclosed .
RED FLAGS
- Sub-75% attendance in FY2025 (73.0%)—engagement concern .
- Audit Committee lacks SEC financial expert—structural oversight risk (board-level) .
- Equity not performance-based; vesting accelerates at change-in-control—potential misalignment for performance-focused investors .
Notes: No director stock ownership guidelines, hedging policy disclosures, clawback provisions for directors, or say‑on‑pay outcomes specific to director compensation were disclosed in the cited sections. If needed, further review of the full proxy and historical proxies could supplement trend analysis.